Evidence map›Paper›PMID 41461173›Full record

ArticleAmerican journal of perinatology2026

Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.

Pamela Baker, Babajide Keshinro, Barbara Stegmann, Abbie Oey, Cathye Shu, Dirk Heerwegh, Rebecca Zaha, Hillary Van Valkenburgh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of perinatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pamela BakerJohnson & Johnson, Spring House, Pennsylvania, United States.
Babajide KeshinroJohnson & Johnson Biologics BV, Leiden, The Netherlands.
Barbara StegmannJohnson & Johnson, Spring House, Pennsylvania, United States.
Abbie OeyJohnson & Johnson, Spring House, Pennsylvania, United States.
Cathye ShuJohnson & Johnson, Spring House, Pennsylvania, United States.
Dirk HeerweghJohnson & Johnson, Beerse, Belgium.
Rebecca ZahaJohnson & Johnson, Spring House, Pennsylvania, United States.
Hillary Van ValkenburghJohnson & Johnson, Spring House, Pennsylvania, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abstract: This article is a plain language summary of publication (PLSP) of the following articles: "Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-1)" by Tiller et al published in

Indexed as

Antibodies, Monoclonal, HumanizedThrombocytopenia, Neonatal AlloimmuneClinical Trials, Phase III as TopicDouble-Blind MethodFemaleHumansImmunoglobulins, IntravenousInfant, NewbornPlain Language SummariesPregnancyRandomized Controlled Trials as TopicResearch DesignAntibodies, Monoclonal, HumanizedImmunoglobulins, Intravenousnipocalimab

Identifiers

PMID41461173
PMCPMC13275166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.